LexaGene Completes Development of Antibiotic Resistance Panel

LexaGene Holdings, Inc., a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has completed the development of an antibiotic resistance marker panel comprised of 12 assays targeting antibiotic resistance genes commonly found in bacterial pathogens. This further expands the Company’s capabilities in providing a complete testing solution for veterinarians to rapidly determine the cause of an infection and whether any antibiotic resistance factors are present.  This information can then be used to prescribe the most effective therapy.